What's Happening?
A 26-week randomized clinical trial has concluded that metformin does not improve insulin resistance in adults with type 1 diabetes. Despite previous studies suggesting benefits in adolescents, this trial found
no significant changes in liver, muscle, or adipose tissue insulin resistance. However, metformin was associated with a reduction in daily insulin dosage, indicating potential metabolic impacts independent of insulin resistance. The study also noted an increase in serum GDF15 levels, a cytokine linked to metabolism, suggesting alternative pathways through which metformin may affect glucose metabolism.
Why It's Important?
The findings challenge the use of metformin as a treatment for insulin resistance in type 1 diabetes, potentially impacting clinical practices and patient management strategies. While metformin's ability to reduce insulin dosage could offer cardiovascular benefits, the lack of improvement in insulin resistance raises questions about its efficacy in this context. The study highlights the need for further research into alternative treatments and mechanisms, particularly those that address cardiovascular risks associated with type 1 diabetes.
